Drug discovery and developer Nexo therapeutics has launched out of stealth with USD 60 million in Series A funding. The round was led by Versant Ventures, with participation from New Enterprise Associates and Cormorant Asset Management.
The funds will be used to develop its platform.
Nexo Therapeutics is a small molecule oncology company focusing on discovering and developing drugs for cancer patients who lack effective therapies. Its platform addresses challenges in ligand discovery and optimization by combining a chemistry engine (CODON) and a chemical biology capability (INFINI-T). This allows Nexo to pursue challenging, high-value targets and expedite drug candidates' development.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.